Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
04 mai 2017 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
20 mars 2017 07h30 HE
|
Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
07 mars 2017 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
08 janv. 2017 16h00 HE
|
Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
04 janv. 2017 17h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
28 nov. 2016 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
09 nov. 2016 16h30 HE
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
03 nov. 2016 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...
Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
01 nov. 2016 16h30 HE
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
04 août 2016 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...